APT3711 oral / Ampeptec - LARVOL DELTA

APT3711: a potential once-monthly injectable for obesity and type 2 diabetes (EASD 2026) - "Based on this relationship, the projected human half-life of APT3711 is estimated at ~420-450 h, potentially exceeding that of the Phase 2b GLP-1 analog MET-097i... These findings indicate that APT3711 combines potent metabolic activity with significantly prolonged pharmacokinetics in preclinical models. The extended half-life observed across species supports the potential development of APT3711 as a once- monthly injectable therapy for obesity and type 2 diabetes. The PK profile may also enable development of a once-weekly oral formulation, potentially improving patient convenience and adherence compared with current GLP-1 therapies."

Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus